15 hasil untuk "Jason Valent"
Menampilkan 1–15 · 1,14 detik · RSS
-
Artikel Jurnal
Myonecrosis in Sickle Cell Anemia—Overlooked and Underdiagnosed
Medical literature detailing muscular complications of sickle cell anemia is sparse and limited to a few case-reports. Features consistent with myositis and myonecrosis are often overlooked and patients are inadequately treated, leading to unforeseen complications. We report an interesting case of…
-
Artikel Jurnal
Solitary extramedullary plasmacytoma of the penis
Solitary extramedullary plasmacytomas are rare plasma cell malignancies, particularly outside the upper aerodigestive tract. A 90-year-old male presented with a penile mass suspicious for penile carcinoma. Pathology revealed the tumor to be an Epstein-Barr virus-associated plasmacytoma with no…
-
Artikel Jurnal
Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)
Of the variety of immunoglobulin related amyloidosis (AL), immunoglobulin M (IgM) related AL represents only 6 to 10% of affected patients, and the majority of these cases are associated with underlying non-Hodgkin’s Lymphoma including Waldenström’s macroglobulinemia (WM). Ibrutinib, acalabrutinib…
-
Artikel Jurnal
Disparities in time to treatment with oral antimyeloma medications
Abstract This retrospective cohort study used Taussig Cancer Center’s Myeloma Patient Registry to identify adults with multiple myeloma diagnosed between January 2017-December 2021. Electronic health records data captured time from diagnosis to initial prescription fill for oral antimyeloma…
-
Artikel Jurnal Teks lengkap
Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
Introduction: Randomized studies have shown that bortezomib (BTZ) can be given weekly via intravenous (IV) route or twice weekly via subcutaneous (SC) route with lower neuropathy risk and no loss of anti-myeloma efficacy compared to original standard IV twice weekly schedule. Weekly SC should…
Juga tersedia di: DOAJ
-
Artikel Jurnal
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
Abstract Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosomal material leading to uncontrolled proliferation in the bone marrow. Ethnic and racial disparities persist in the prevalence, diagnosis, management, and outcomes of MM…
-
Artikel Jurnal
Triplet or Quadruplet Regimen Utilization and Overall Survival in Patients Diagnosed With Multiple Myeloma Between 2017 and 2023
ABSTRACT Introduction Multiple myeloma treatment has rapidly evolved, but little is known about the uptake of guideline‐recommended triplet or quadruplet therapy in clinical practice. Methods This retrospective cohort study included adult patients newly diagnosed with multiple myeloma between…
-
Artikel Jurnal
Limited duration of dexamethasone in newly diagnosed AL amyloidosis: impact on response, toxicity, and survival
Background Systemic light chain amyloidosis (AL) is a life-threatening disease in which dexamethasone (Dex) is a core therapy but is limited by cumulative toxicity. The optimal duration of Dex, particularly in the era of daratumumab (Dara)-based regimens, is uncertain.Methods We retrospectively…
-
Artikel Jurnal
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
Abstract Venetoclax is efficacious in relapsed/refractory t(11;14) multiple myeloma, thus warranting investigation in light-chain amyloidosis (AL). This retrospective cohort includes 43 patients with previously treated AL, from 14 centers in the US and Europe. Thirty-one patients harbored t(11;14)…